TCM
EDIT icon

Telos Capital Management’s Editas Medicine EDIT Stock Holding History

Telos Capital Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-5,655
Closed -$203K – 158
2018
Q2 		$203K Buy
+5,655
New +$200K 0.07% 148

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Telos Capital Management's EDIT Position: Q3 2018 in Review

Telos Capital Management sold out of Editas Medicine (EDIT) in Q3 2018, closing a stake of 5,655 shares — an estimated $203K sold.

Telos Capital Management first reported a position in EDIT in Q2 2018 and held it in 1 quarter. The position peaked at $203K in Q2 2018. 199 funds tracked by Wall St. Rank hold EDIT as of Q3 2018.

  • Telos Capital Management reported no remaining Editas Medicine position as of Q3 2018 after selling out during the quarter.
  • Telos Capital Management sold 5,655 Editas Medicine shares in Q3 2018, an estimated $203K.
  • Telos Capital Management first reported a position in Editas Medicine in Q2 2018 and held it in 1 quarter.
  • Telos Capital Management's Editas Medicine position peaked at $203K in Q2 2018.
  • 199 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2018.

Based on Telos Capital Management's 13F filing for Q3 2018, filed 26 Oct 2018.